Language:
Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
labmedica.com
Microbiology
Features Subscription Partner Sites Journal Info
Veolia WATERRANDOX LABORATORIESAB SCIEX

Rapid Tests Preemptively Screen Drug Resistant Bacteria

By Labmedica International staff writers
Posted on 31 May 2012


Rapid diagnostic testing (RDT) can be used to screen carriers of suspected methicillin-resistant Staphylococcus aureus (MRSA) in hospitals.

Preemptive isolation of suspected MRSA carriers is a cornerstone of successful MRSA control policies but is hampered when using conventional cultures with diagnostic delays of three to five days, as many noncarriers remain unnecessarily isolated.

Scientists at the University Medical Center (Utrecht, The Netherlands) investigated whether RDT reduces the amount of unnecessary isolation days, the costs, and benefits in intensive care units (ICUs) in a multicenter hospital-wide study. The effects of RDT of MRSA was evaluated using polymerase chain reaction (PCR) assays added to screening with conventional microbiological culture methods for patients eligible for MRSA screening. Two real time PCR assays were subsequently evaluated: BD GeneOhm MRSA PCR between December 2005 and May 2007, and Xpert MRSA assay between April 2007 and June 2008.

A total of 163 patients at risk for MRSA carriage were screened and MRSA prevalence was 3.1%. Duration of isolation was 27.6 hours with BD GeneOhm MRSA PCR (previously known as IDI-MRSA, BD Diagnostics, San Diego, CA, USA) and 21.4 hours with GeneXpert (Cepheid, Sunnyvale, CA, USA), and would have been 96 hours when based on conventional cultures. The negative predictive value was 100% for both tests.

Numbers of isolation days were reduced by 44.3% with PCR-based screening at the additional costs of EUR 327.84 for the BD assay and EUR 252.14 for the GeneXpert test per patient screened. Costs per isolation day avoided were calculated to be EUR 136.04 for the BD assay and EUR 121.76 for the GeneXpert. The authors concluded therefore that in a low endemic setting for MRSA, RDT safely reduced the number of unnecessary isolation days.

The platforms used are not suited for the large volumes of multiple tests in a short period of time, as only 16 could be performed simultaneously on Cepheid's Smartcycler and four tests on the GeneXpert systems. This endorses the need for large volume testing or pooling of swabs in ICU patients to decrease unnecessary preemptive isolation time. Another option would be to use chromogenic agar-based screening, which has a slightly longer turn around time in the laboratory, but can be performed in large volumes and is easily implemented in routine laboratory practice, including weekends. The study was originally published on February 7, 2012, in the journal Critical Care.

Related Links:
University Medical Center Utrecht
BD Diagnostics
Cepheid




Ovarian Cancer Immunoassay
Ovarian Cancer Immunoassay
Upright Microscope
Upright Microscope
Chemistry Analyzer
Chemistry Analyzer

More Products

Latest Microbiology News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
SIEMENS DIAGNOSTICS :
Siemens Healthcare Diagnostics Anti-CCP: A Clinical Evaluation Whitepaper

Download Whitepaper
Events
ELA – European Lab Automation congress
06 Jun 2013 - 07 Jun 2013


European Human Genetics Conference 2013
08 Jun 2013 - 11 Jun 2013


8th Forum on Oxidative Stress and Aging
12 Jun 2013 - 14 Jun 2013


More events
GLOBETECH PUBLISHING
Latest Issue

View Digital Edition
Subscribe / Renew
AACC
BioPorto Diagnostics
KARL HECHT GMBH & CO KG
GREINER-BIO-ONE
77 ELEKTRONIKA
DIASOURCE
ALTO MARKETING LIMITED
  labmedica.com Copyright © 2000-2013 Globetech Media. All rights reserved.
Privacy Policy